Adolore Biotherapeutics Enters Exclusive License Agreement with University of Miami for Patents Protecting Non-Enzymatic Carbonic Anhydrase DNA Constructs and Their Protein Products and Uses

by AdoloreJTC24 | May 16, 2023 | Press Releases

Company developing next generation, disease-modifying, non-opioid analgesic gene therapies for the treatment of chronic painDELRAY BEACH, FL / May 16, 2023 / Adolore Biotherapeutics, Inc. (“Adolore” or the “Company”) a biotechnology company...

Adolore Biotherapeutics to Present Its Gene Therapy Program for Chronic Pain at the 4th Annual National Institutes of Health (NIH) HEAL Initiative Investigator Meeting

by AdoloreJTC24 | Feb 22, 2023 | Press Releases

DELRAY BEACH, FL / February 22, 2023 / Adolore Biotherapeutics, Inc. (“Adolore” or the “Company”) a biotechnology company focused on developing breakthrough opioid-free pain relieving (analgesic) treatments for pain, today announced that Dr....

Adolore Biotherapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

by AdoloreJTC24 | Jan 18, 2023 | Press Releases

Live video webcast presentation on Thursday, January 19th at 10:00 AM ETDELRAY BEACH, FL / January 18, 2023 / Adolore Biotherapeutics, Inc. (“Adolore” or the “Company”) a biotechnology company focused on developing breakthrough opioid-free pain...

Adolore Biotherapeutics Strengthens Management Team and Board of Directors with the Appointments of Roelof Rongen, MSE, MBA and Mark C. Rogers, MD, MBA

by AdoloreJTC24 | Jan 17, 2023 | Press Releases

Mr. Rongen appointed as CEO and member of the Board bringing 30 years of executive leadership experience and expertise across a number of therapeutic areasBolstered expertise on Board of Directors with addition of Dr. Rogers who brings significant leadership and...

Adolore BioTherapeutics Invited to Present at the 16th Annual Pain Therapeutics Summit

by AdoloreJTC24 | Nov 14, 2022 | Press Releases

Company to discuss its next generation, disease-modifying, non-opioid analgesic gene therapy in development for the treatment of chronic painDELRAY BEACH, FL / November 14, 2022 / Adolore BioTherapeutics, Inc. (“Adolore” or the “Company”), a...